Abacus Global Management enters its June 3 earnings with a notable flag already on the tape — five executives sold shares on the same day, just three weeks before the next print.
The insider activity from May 8 is the clearest signal this week. The CEO Jay Jackson sold nearly 96,000 shares at $9.08, raising roughly $870,000. Three co-founders — McNealy, Ganovsky, and Kirby — each sold 27,773 shares on the same date. CFO Bill McCauley added another 46,927 shares to the pile. In total, net insider selling over the past 90 days amounts to roughly $2.3 million across 257,000 shares. The coordinated nature of the May 8 cluster — five C-suite sellers, same price, same day — stands out even if each transaction was individually modest relative to the founders' still-sizeable stakes of roughly 13% each.
The stock has since recovered. ABX closed at $9.56 on May 26, up 8.1% on the week and 5.8% on the day, which means the May 8 sellers left money on the table. Whether that reflects pre-planned disposal schedules or timing judgment is not clear from the data alone, but the rebound creates an interesting backdrop heading into June 3.
Short positioning is restrained but not absent. The ORTEX short score reads 77.9 — a high reading that reflects the overall configuration of the borrow market rather than a crowded short book. Actual short interest is modest, with around 6 million shares shorted. Borrow availability has loosened noticeably over the past week, moving from roughly 68% to 85% — more shares are now available relative to the existing short position, suggesting no acute squeeze pressure in the lending market. Cost to borrow ticked up 6.5% on the week to 1.23%, which is elevated from a brief dip to 0.46% in mid-May but remains well within the range seen since April. Borrow is cheap and getting slightly more expensive, but nothing here signals stress.
Options traders are mildly more cautious than usual, though not dramatically so. The put/call ratio moved to 0.44, slightly above its 20-day average of 0.39. That's less than one standard deviation above the mean — not a red-flag reading. The 52-week PCR range runs from 0.23 to 2.12, so current positioning looks closer to the bullish end of the spectrum historically, even accounting for the modest pickup in puts this week.
The Street's positioning is thin but legible. Piper Sandler's analyst Crispin Love has been the primary voice of record, downgrading the stock from Overweight to Neutral in March and trimming the target from $11 to $9.50 in April before nudging it back to $10 after the May earnings print. The consensus mean target is $13.58, which implies meaningful upside from current levels — though with limited analyst coverage and a single firm driving recent changes, that figure deserves to be held lightly. The bull case centres on 60% adjusted net income growth projected for 2025 (guidance of $70–78 million) and the company's ability to capitalise on demand for life insurance monetisation during volatile markets. Bears point to sluggish revenue in core segments, heavy U.S. concentration, and margin pressure from rising competition in alternative asset management. The P/E ratio of roughly 9x and EV/EBITDA near 8x reflect a modest valuation for a company guiding for that level of earnings growth, though the lack of market cap data makes it harder to frame the size-adjusted picture precisely.
The next event to watch is the June 3 earnings release. The most recent print — in May — produced a 3.8% one-day decline and a further 2.9% slip over the following five days, so the stock's recent habit around results skews negative in the short run even when the underlying guidance has been constructive.
See the live data behind this article on ORTEX.
Open ABX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
